Agios Pharmaceuticals announced it will stop developing tebapivat, a drug for sickle cell disease, after Phase 2 trial results failed to meet expectations. Following this news, the company's stock price fell 6.74%. Pomerantz LLP is investigating whether Agios and its executives engaged in securities fraud or unlawful business practices related to this announcement. Investors affected by this situation are encouraged to contact the law firm for potential class action participation.
Metaplanet has updated its capital allocation policy to hold 85% to 90% of its assets in Bitcoin, with 10% to 15% allocated to acquisitions and investments that generate recurring income. The company aims to fund most Bitcoin purchases with permanent...
AtlasClear Holdings announced stock option awards for its executive leaders and board members to support long-term retention and align interests with shareholders. The options, granted on October 1, 2026, allow purchase of shares at $0.2010 each and ...
Valor Gold Corp. announced the sudden illness and passing of its CEO, Mark Ashley, a respected leader and mentor. Alan Edwards, the Chairman, will serve as interim CEO, ensuring leadership continuity as the company advances its gold exploration proje...
PEPE meme coin surged to around $0.00000453 on October 5, surpassing the $0.00000445 resistance level after recovering from a recent selloff. Technical analysis suggests a bullish Wolfe Wave pattern that could push PEPE's price to approximately $0.00...
David Borde has been appointed president and CEO of Entergy Texas, effective October 5, 2026, succeeding Eliecer Viamontes who left for other opportunities. Borde has extensive experience in utility strategy, regulatory affairs, and finance, having s...
